RE:RE:RE:WHAT THE #r%#$I have no idea what was said on BNN but that Oct 29th NR made it worth a bet in the 30's even in the face of potentially successful vaccines, particularly this part:
"
Initially, more than 1,000 kits have been ordered, comprised of tens of thousands of swabs (units). This represents over CDN$ 500,000 in sales, with customer projections of continuing growth. A first material ONBOARDx shipment has now been completed, and in Q1 calendar 2021, Microbix is enhancing its FLOQSwab-based QAPs supply-chain to support production of up to 50,000 units per month." Margins on business appear to be mid-40's but I've had to "hold my nose" with regard to former poor choices by management and the relatively poor state of the balance sheet, but it is after all just a microcap.and these QAP's just might turn out to be a sustainable rev op..